Acurx (NASDAQ: ACXP) director gets 2,150 stock options grant

Rhea-AI Filing Summary

Acurx Pharmaceuticals director Jack H. Dean received a compensatory stock option award for service on the company’s board. The grant covers 2,150 shares of common stock at an exercise price of $2.36 per share, expiring on April 20, 2036.

The option was granted at no cost and is scheduled to vest in full on April 20, 2027 under Acurx’s Director Compensation Policy. This Form 4 reports an option grant only; it does not show any open‑market purchases or sales of Acurx common stock by the director.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider DEAN JACK H

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	2,150	$0.00	--

Holdings After Transaction: Stock Option — 2,150 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 2,150 options Exercise price: $2.36 per share Expiration date: April 20, 2036 +3 more

6 metrics

Stock options granted 2,150 options Director grant on April 20, 2026

Exercise price $2.36 per share Strike price for option grant

Expiration date April 20, 2036 Option term end date

Underlying shares 2,150 shares Common stock subject to options

Shares after transaction 2,150 derivative securities Total options held following grant

Vesting date April 20, 2027 Options vest per Director Compensation Policy

Key Terms

Stock Option, Director Compensation Policy, vesting, underlying security

4 terms

Stock Option financial

"security_title: "Stock Option""

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

Director Compensation Policy financial

"granted pursuant to the Issuer's Director Compensation Policy"

vesting financial

"The shares subject to the options shall vest on April 20, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

underlying security financial

"underlying_security_title: "Common Stock" and underlying_security_shares"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DEAN JACK H

(Last) (First) (Middle)

C/O ACURX PHARMACEUTICALS, INC.,

259 LIBERTY AVENUE

(Street)

STATEN ISLAND NEW YORK 10305

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Acurx Pharmaceuticals, Inc. [ ACXP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$2.36	04/20/2026		A		2,150(1)		04/20/2027	04/20/2036	Common Stock	2,150	$0	2,150	D

Explanation of Responses:

1. This stock option award is related to service on the Issuer's board of directors granted pursuant to the Issuer's Director Compensation Policy. The shares subject to the options shall vest on April 20, 2027.

	/s/ Kostantinos Skordalos, Power of Attorney For: Jack H. Dean	04/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Acurx Pharmaceuticals (ACXP) report on this Form 4?

Acurx reported a stock option grant to director Jack H. Dean. He received options over 2,150 shares of common stock as board compensation, not through open‑market trading, with future vesting and a fixed exercise price.

How many Acurx (ACXP) shares are covered by Jack H. Dean’s new stock options?

The option grant covers 2,150 underlying shares of Acurx common stock. These shares are only issuable if the options vest and are exercised, reflecting equity-based compensation rather than an immediate share purchase or sale in the market.

What is the exercise price and term of Jack H. Dean’s Acurx (ACXP) stock options?

The options have an exercise price of $2.36 per share and expire on April 20, 2036. This gives the director a long-dated right to buy Acurx common stock at that fixed price if the award vests.

When do Jack H. Dean’s Acurx (ACXP) stock options vest according to the Form 4?

The options are scheduled to vest on April 20, 2027. Vesting is tied to his service on Acurx’s board of directors under the company’s Director Compensation Policy, meaning he must remain in service to earn the full award.

Did the Acurx (ACXP) Form 4 show any insider buying or selling of common stock?

No, the Form 4 reports only a grant of stock options, not market trades. It shows an award acquisition of derivative securities as board compensation, with no open‑market purchases or sales of Acurx common stock disclosed in this filing.